Product Information
TALTZ 80 MG/ML AUTOINJECTOR (3-PACK) is a brand product labeled by Eli Lilly and Company, priced at $7388.2220 per ML under NDC 00002144509. Its NADAC has been published 89 times since Aug 21, 2024.
Strength
80 mg/mL
Manufacturer
Eli Lilly and CompanyNDC
00002144509
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
IXEKIZUMABApproval Type
Biologic (BLA)
FDA Application
BLA125521On Market Since
3/22/2016
Pharmacological Classes
Price Statistics
The NADAC for TALTZ 80 MG/ML AUTOINJECTOR (3-PACK) has been published 89 times since Aug 21, 2024, and over the history we have for it it has risen 10.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7388.2220 per ML |
|---|---|
| All-time high | $7388.2220 (Sep 30, 2026) |
| All-time low | $6663.7107 (Aug 21, 2024) |
| 52-week high | $7388.2220 |
| 52-week low | $7020.1327 |
| Median price | $7020.1327 |
| Average price | $7005.2297 |
| Largest weekly change | +5.0% (Jan 8, 2025) |
| Weeks tracked | 89 |
| Tracking since | Aug 21, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ixekizumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Interleukin-17A Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TALTZ 80 MG/ML AUTOINJECTOR (3-PACK)?
The current National Average Drug Acquisition Cost (NADAC) for TALTZ 80 MG/ML AUTOINJECTOR (3-PACK), manufactured by Eli Lilly and Company, is $7388.2220 per ML (NDC 00002144509), effective Sep 30, 2026.
How has the price of TALTZ 80 MG/ML AUTOINJECTOR (3-PACK) changed over time?
Over the history we have for it, the NADAC for TALTZ 80 MG/ML AUTOINJECTOR (3-PACK) has risen 10.9%. It has been tracked across 89 weekly CMS publications since Aug 21, 2024.
What are the highest and lowest recorded NADAC prices for TALTZ 80 MG/ML AUTOINJECTOR (3-PACK)?
Since Aug 21, 2024, the NADAC for TALTZ 80 MG/ML AUTOINJECTOR (3-PACK) has ranged from a low of $6663.7107 (Aug 21, 2024) to a high of $7388.2220 (Sep 30, 2026), with a median of $7020.1327 per ML.
Are there cheaper alternatives to TALTZ 80 MG/ML AUTOINJECTOR (3-PACK)?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TALTZ 80 MG/ML AUTOINJECTOR, is $7370.7151 per ML — about 0% below TALTZ 80 MG/ML AUTOINJECTOR (3-PACK).
Who manufactures TALTZ 80 MG/ML AUTOINJECTOR (3-PACK)?
TALTZ 80 MG/ML AUTOINJECTOR (3-PACK) (NDC 00002144509) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.